Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Naurex, Inc, an affiliate of Allergan plc
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completion of Study RAP-MD-30, RAP-MD-31, or RAP-MD-32
If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test
You may not be if
DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
Lifetime history of meeting DSM-5 criteria for:
1.Schizophrenia spectrum or other psychotic disorder
2.Bipolar or related disorder
3.Major neurocognitive disorder
4.Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
5.Dissociative disorder
6.Posttraumatic stress disorder
7.MDD with psychotic features
Significant suicide risk, as judged by the Investigator
Clareo Health | Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
